English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objective: Pertuzumab, a new recombinant humanized monoclonal antibody, has been developed to inhibit the formation of HER2:HER3 heterodimerization. The clinical benefit of pertuzumab therapy in HER2 positive metastatic Breast Cancer (mBC) patients in the first -line setting has been shown in previous phase III studies. Herein we aimed to analyze the efficacy and toxicity profile of pertuzumab in patients with HER2 positive mBC. Materials and Methods: This was a retrospective study of 28 patients with mBC followed from two different centers in Turkey. All patients were treated with pertuzumab in the first line setting, with a combination including trastuzumab and docetaxel. Treatment outcomes along with drug efficacy and safety were retrospectively analyzed. Results: At a median follow-up time of 10.1 (2.4-25.2) months, among the 28 patients, 1 (3.6%) case of death and 2 (7.1%) cases of progression occurred. The median age was determined as 47 (18-74) years. Excluding 1 patient, all had (96.4%) de-novo metastatic disease at presentation. The median number of treatment cycles was 7 (4 12) for docetaxel, 18 (4 35) for pertuzumab + trastuzumab, and 10 (1 29) for the maintenance therapy (pertuzumab + trastuzumab). The most common side effects were fatigue (75%) and arthralgia/myalgia (64.3%). Grade 3 or 4 toxicity was observed to be very infrequent as follows: neutropenia; grade 3 in 4 (14%) patients and grade 4 in 1 (3.6%) patient, neuropathy; grade 3 in 5 (17.8%) patients. Conclusion: Even with a small sample size, our results confirm that pertuzumab + trastuzumab + docetaxel combination therapy in the first line setting for HER2 positive mBC patients is the standard of care, with acceptable toxicity profile.

Treatment Outcomes of HER-2 Positive Metastatic Breast Cancer Patients Treated with Pertuzumab in the First Line Setting- Real Life Experience